NCT05288816View on ClinicalTrials.gov

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

July 5, 2017

Study Completion Date

July 5, 2017

Conditions
Healthy
Interventions
DRUG

ALXN1210

Participants received a single dose (400 mg or 800 mg) and multiple doses (800 mg) of ALXN1210.

Trial Locations (1)

Unknown

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY